Middleway Nutrition
Evidence-based GLP-1 and peptide science.
Clear clinical research, dosing context, safety tradeoffs, and practical guides organized into two focused archives.
Latest Articles
20 articles
GLP-1 and Kidney Disease: FLOW Trial Data and Ozempic's FDA-Approved CKD Indication
FDA approved Ozempic (semaglutide) on January 28, 2025 to slow kidney disease progression in adults with type 2 diabetes and CKD. The FLOW trial in 3,533 patients showed a 24% reduction in major kidney events — independent of weight loss.
GLP-1How to Boost GLP-1 Naturally: Foods, Exercise, and Habits That Actually Work
Your body makes GLP-1 every time you eat — but DPP-4 destroys it within 1-2 minutes. Protein, soluble fiber, healthy fats, fermented foods, and exercise amplify the pulse. Here's the evidence-based playbook.
GLP-1GLP-1 for Heart Failure: STEP-HFpEF, SUMMIT, and Why HFpEF Is Where the Data Lives
Semaglutide and tirzepatide both improve symptoms in obesity-related HFpEF. STEP-HFpEF: +7.8 KCCQ points, -13.3% weight. SUMMIT: 38% lower risk of CV death or worsening heart failure with tirzepatide.
GLP-1GLP-1 Face (Ozempic Face): Mechanism, Prevention, and What Actually Treats It
Dermatologist Dr. Paul Jarrod Frank coined the term in 2022. Beyond rapid weight loss, new research shows GLP-1 receptors directly affect adipose stem cells, fibroblasts, and collagen synthesis — explaining why the face ages faster than the rest of the body.
GLP-1GLP-1 Recipes: 15 High-Protein Meals That Won't Trigger Nausea (2026)
Fifteen specific GLP-1-friendly recipes with exact ingredients, protein grams, calorie counts, and gentle cooking methods. Plus a sample 100g protein day and a list of dishes to avoid because of GI side effects.
GLP-1GLP-1 Lawsuits 2026: Where MDL-3094 and MDL-3163 Stand Today
More than 3,600 federal lawsuits allege gastroparesis, NAION blindness, and other injuries from GLP-1 drugs. Bellwether trials are expected mid-2026. Here is the full status.
GLP-1GLP-1 Online: The 9 Telehealth Providers Worth Knowing in 2026
The compounded free-for-all is over. After the FDA cleared the shortage list and sent 55+ warning letters, GLP-1 telehealth split into branded-only and compounded-503A camps. Here is each major provider's real pricing, medication list, and trade-offs.
GLP-1GLP-1 vs GLP-2: Same Gene, Two Completely Different Drug Classes
GLP-1 and GLP-2 come from the same proglucagon gene and are released by the same intestinal cells — but they hit different receptors, do different jobs, and treat completely different diseases. One is the basis of Ozempic. The other is the basis of a $300,000-a-year drug for short bowel syndrome.
GLP-1GLP-1 Near Me: How to Find a Local Prescriber in 2026
Four local paths to a GLP-1 prescription — primary care, obesity medicine clinics, retail clinics like MinuteClinic, and med spas. What each charges, what they include, and how to vet.
GLP-1GLP-1 for Fatty Liver: Wegovy's August 2025 MASH Approval, ESSENCE Trial Data, and How Semaglutide, Tirzepatide, and Retatrutide Compare
FDA approved Wegovy (semaglutide) on August 15, 2025 as the first GLP-1 for MASH with moderate-to-advanced fibrosis. ESSENCE trial: 62.9% steatohepatitis resolution vs 34.3% placebo, 36.8% fibrosis improvement vs 22.4%.
GLP-1Which GLP-1 Is Best for Weight Loss? The 2026 Decision Matrix
Tirzepatide produces the most pure weight loss of any approved GLP-1 — 20.9% in SURMOUNT-1 and 20.2% vs semaglutide's 13.7% in the head-to-head SURMOUNT-5. But \"best\" depends on whether your goal is maximum loss, cardiovascular protection, kidney protection, OSA, no needles, or lowest cost.
GLP-1GLP-1 Injection Sites: Abdomen, Thigh, or Arm — and Why Rotation Matters
All three FDA-approved sites work, but absorption from the thigh is about 12% lower than the abdomen. The bigger issue is rotation — up to two-thirds of users develop lipohypertrophy without it.
GLP-1GLP-1 Long Term Side Effects: 5+ Years of Trial and Real-World Data
Most GLP-1 side effects fade after 3-6 months. What persists matters more — muscle loss in 25-40% of weight lost without strength training, gallbladder disease at 2x rate, and the NAION signal for semaglutide.
GLP-1GLP-1 Benefits Beyond Weight Loss: 13 Conditions With Real Evidence in 2026
GLP-1 drugs are FDA approved for diabetes, cardiovascular disease, kidney disease, sleep apnea, and MASH. Active research covers Alzheimer's, addiction, COVID, fertility, cancer, asthma, and arthritis. Here is the evidence.
GLP-1GLP-1 Contraindications: The Complete Absolute and Relative List (2026)
Some conditions absolutely rule out GLP-1 medications. Others require caution and monitoring. Here is every contraindication for semaglutide and tirzepatide — and the conditions people wrongly think disqualify them.
GLP-1GLP-1 Pills: The 3 FDA-Approved Oral Options Compared (2026)
Foundayo, oral Wegovy, and Rybelsus are the three FDA-approved GLP-1 pills as of 2026. Here is the full breakdown — exact doses, trial weight loss, food rules, prices, and what the head-to-head data show.
GLP-1GLP-1 Patches: Do They Work? Full 2026 Review With Brand Breakdowns
GLP-1 patches sold online do not contain semaglutide or tirzepatide. The molecules are too large for skin to absorb, brands rely on supplement ingredients, and amazon ratings on the leading patches sit at 1.8–2.1 stars.
GLP-1GLP-1 and Alcohol: What the Drug Label Doesn't Tell You About Drinking on Ozempic
There's no warning on the GLP-1 label about alcohol, but tolerance changes, nausea spikes, hypoglycemia risk rises, and clinical trials show reduced cravings. Here is what the evidence and the prescribers actually say.
GLP-1GLP-1 and Blindness: The NAION Evidence in 2026 (And Why It's More Nuanced Than Headlines)
A 2024 JAMA Ophthalmology study found 4–7× higher NAION risk on semaglutide. A 2026 cohort study of 370,000 patients found no statistically significant increase — and a 24% reduction in overall blindness. Here is the full picture.
GLP-1GLP-1 for Sleep Apnea: SURMOUNT-OSA Data and Why Zepbound Became the First Approved OSA Drug
FDA approved Zepbound (tirzepatide) on December 20, 2024 as the first prescription medication for obstructive sleep apnea in adults with obesity. Trial: 25–29 fewer breathing events per hour, 18–20% weight loss.